Skip to main content

Table 1 In a multivariate analysis of recurrent breast cancer cases, the expression of YB-1 was better than HER-2 or ER in predicting events

From: Redefining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease-specific survival than estrogen receptor or HER-2 across all tumor subtypes

Prognostic marker Patients with relapse
  HR (95% CI) P value
Nodal status   
   Positive versus negative 1.951 (1.725 to 2.206) 1.7 × 10-26
Tumor size (cm)   
   2 to 5 1.392 (1.227 to 1.579) 2.8 × 10-7
   >5 1.921 (1.227 to 2.445) 1.2 × 10-7
Grade   
   III versus II versus I 1.300 (1.139 to 1.482) 9.6 × 10-5
Age (years)   
   <50 versus ≥ 50 1.000 (0.878 to 1.139) 1.000
ER   
   Positive versus negative 0.942 (0.816 to 1.087) 0.41
HER-2   
   Positive versus negative 1.256 (1.066 to 1.479) 6.0 × 10-3
YB-1   
   Positive versus negative 1.331 (1.169 to 1.516) 1.6 × 10-5
  1. The predictive power of YB-1 was similar to that of tumor grade and smaller tumor size, but not as great as that of nodal status. CI, confidence interval; ER, estrogen receptor; HER, human epidermal growth factor receptor; HR, hazard ratio; YB-1 = Y-box binding protein-1.